| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| April 29, 2026 | ±5.1% | +0.7% | over-priced |
| October 30, 2025 | ±4.1% | -0.3% | over-priced |
| May 1, 2025 | ±3.9% | -0.6% | over-priced |
| October 31, 2024 | ±4.5% | -0.6% | over-priced |
| July 29, 2024 | ±3.3% | +1.1% | over-priced |
| May 2, 2024 | ±3.0% | -0.2% | over-priced |
| October 26, 2023 | ±4.1% | -1.6% | over-priced |
| August 2, 2023 | ±2.9% | -1.6% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $7.15 | $19.1B | $1.9B |
| Q3 FY2025 | $6.96 | $19.2B | $1.9B |
| Q2 FY2025 | — | $0 | $0 |
| Q1 FY2025 | $6.45 | $18.3B | $1.8B |
HCA Healthcare, Inc. (HCA) reports in 114 days, with the next report estimated for October 5, 2026. Across the last 8 reports, options priced an average ±3.9% earnings move while the stock actually moved 0.8% on average — the market has systematically over-priced HCA's earnings risk. Fundamentals into the print: EPS up 46.5% year-over-year, revenue up 9.3%. QuantLogix's live 5-factor engine currently reads HCA as a neutral at 49/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →